Last quarter (Q ), Voyageur Pharmaceuticals's total revenue was C$―, a decrease of ― from the same quarter last year. In Q, Voyageur Pharmaceuticals's net income was C$-273.60K. See Voyageur Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Nov 23	Nov 22	Nov 21	Nov 20	Nov 19
Total Revenue	-	-	-	-	C$ 0.00	C$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	C$ 1.35M	C$ 1.35M	C$ 1.75M	C$ 2.05M	C$ 1.00M	C$ 554.89K
Operating Income	C$ -1.35M	C$ -1.35M	C$ -1.75M	C$ -2.05M	C$ -1.00M	C$ -554.89K
Net Non Operating Interest Income Expense	-	-	-	-	-	-
Other Income Expense	C$ 53.09K	C$ 53.09K	C$ 1.97K	-	C$ -138.38K	C$ 2.60K
Pretax Income	C$ -1.40M	C$ -1.40M	C$ -1.75M	C$ -2.05M	C$ -1.14M	C$ -552.29K
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	C$ -1.40M	C$ -1.40M	C$ -1.75M	C$ -2.05M	C$ -1.14M	C$ -552.29K
Basic EPS	-	C$ -0.01	C$ -0.02	C$ -0.02	C$ -0.02	C$ -0.01
Diluted EPS	-	C$ -0.01	C$ -0.02	C$ -0.02	C$ -0.02	C$ -0.01
Basic Average Shares	C$ 522.02M	C$ 130.50M	C$ 107.83M	C$ 94.68M	C$ 70.53M	C$ 57.54M
Diluted Average Shares	C$ 522.02M	C$ 130.50M	C$ 107.83M	C$ 94.68M	C$ 70.53M	C$ 57.54M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	C$ 1.13M	-	C$ 1.75M	C$ -2.05M	C$ 1.00M	C$ 554.89K
Net Income From Continuing And Discontinued Operation	C$ -1.40M	C$ -1.40M	C$ -1.75M	C$ -2.05M	C$ -1.14M	C$ -552.29K
Normalized Income	C$ -931.39K	C$ -980.00K	C$ -1.28M	C$ -1.51M	C$ -987.32K	C$ -552.29K
Interest Expense	-	-	-	-	-	-
EBIT	C$ -1.40M	C$ -1.40M	C$ -1.75M	C$ -2.05M	C$ -1.00M	C$ -554.89K
EBITDA	C$ -1.40M	C$ -1.40M	C$ -1.74M	C$ -2.05M	C$ -999.56K	C$ -552.77K

Currency in CAD

Voyageur Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing